CROX
Crocs, Inc.
CROX has the edge over RIVN overall, supported by stronger fundamentals and lower modeled downside.
RIVN
Rivian Automotive, Inc.
RIVN's outlook is improving, though it still trails on the overall score.
CROX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Strong |
CROX's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
RIVN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
RIVN's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
CROX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7.4x | $97.23 | -38% |
| Forward | 9.9x | $157 | — |
| Fair | 11x | $146 | -7.1% |
| Current | 12x | $157 | — |
| Expensive | 22x | $286 | +82% |
Historical ranges are pointers, not guarantees.
CROX's PE is in its fair range at 12x. If earnings grow as analysts expect, today's price would be 9.9x next year's earnings.
RIVN PE Valuation
RIVN has no meaningful PE right now: it lost money over the past year.
CROX Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for CROX, with profitability improving.
RIVN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect RIVN's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
CROX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $15.91 | +21% |
| Q3 2026 | $13.15 | +344% |
| Q2 2026 | $11.33 | +213% |
| Q1 2026 | -$1.62 | -110% |
| Q4 2025 | -$1.50 | -109% |
| Q3 2025 | $2.96 | -79% |
| Q2 2025 | $3.62 | -73% |
| Q1 2025 | $16.21 | +26% |
| Q4 2024 | $15.88 | +24% |
CROX has the edge over RIVN on earnings quality, reporting a profit while its opponent remains loss making.
RIVN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.25 | +$0.83 |
| Q2 2026 | -$2.58 | +$0.62 |
| Q1 2026 | -$2.92 | +$0.77 |
| Q4 2025 | -$3.07 | +$1.62 |
| Q3 2025 | -$3.08 | +$2.52 |
| Q2 2025 | -$3.20 | +$2.76 |
| Q1 2025 | -$3.69 | +$2.08 |
| Q4 2024 | -$4.69 | +$1.05 |
RIVN is still losing money, but far less than before: $2.25 per share over the past year, against $7.40 at its worst in late 2022.
CROX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1B | +4.6% |
| Q2 2026 | $1.2B | +2.6% |
| Q1 2026 | $921.5M | -1.7% |
| Q4 2025 | $957.6M | -3.2% |
| Q3 2025 | $996.3M | -6.2% |
| Q2 2025 | $1.1B | +3.4% |
| Q1 2025 | $937.3M | -0.1% |
| Q4 2024 | $989.8M | +3.1% |
CROX's revenue grew through 2023 and has held roughly level since: $1B last quarter, up 4.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 28% | +7.2 points |
| Q2 2026 | 24% | +61 points |
| Q1 2026 | 22% | -2 points |
| Q4 2025 | 15% | -4.9 points |
| Q3 2025 | 21% | -4.6 points |
| Q2 2025 | -37% | -67 points |
| Q1 2025 | 24% | -0.3 points |
| Q4 2024 | 20% | -1.6 points |
CROX has the edge over RIVN on profitability, with a higher operating margin.
RIVN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.2B | +38% |
| Q2 2026 | $1.7B | +27% |
| Q1 2026 | $1.4B | +11% |
| Q4 2025 | $1.3B | -26% |
| Q3 2025 | $1.6B | +78% |
| Q2 2025 | $1.3B | +13% |
| Q1 2025 | $1.2B | +3% |
| Q4 2024 | $1.7B | +32% |
RIVN has the edge over CROX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -41% | +22 points |
| Q2 2026 | -50% | +35 points |
| Q1 2026 | -64% | -11 points |
| Q4 2025 | -65% | -27 points |
| Q3 2025 | -63% | +71 points |
| Q2 2025 | -86% | +33 points |
| Q1 2025 | -53% | +70 points |
| Q4 2024 | -38% | +82 points |
RIVN's operating margin was −41% last quarter, up 22 points from the same quarter a year ago, near the top of its range since 2021.
CROX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $275.5M | +22% |
| Q2 2026 | $331M | +23% |
| Q1 2026 | -$98.9M | -$16.3M |
| Q4 2025 | $246.4M | -19% |
| Q3 2025 | $226.2M | -19% |
| Q2 2025 | $269.2M | -30% |
| Q1 2025 | -$82.6M | -$39.3M |
| Q4 2024 | $303.4M | -5.3% |
CROX has the edge over RIVN on cash generation, producing positive trailing cash flow while its opponent burns cash.
RIVN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.1B | -$703M |
| Q2 2026 | -$849M | -$451M |
| Q1 2026 | -$1.1B | -$549M |
| Q4 2025 | -$1.1B | -234% |
| Q3 2025 | -$421M | +$732M |
| Q2 2025 | -$398M | +$639M |
| Q1 2025 | -$526M | +$997M |
| Q4 2024 | $856M | +$2.3B |
RIVN has burned cash in almost every quarter: −$4.2B over the past year, against −$489M the year before.
CROX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -3.4% | -1.7M shares |
| 1 year | -11% | -6M shares |
| 3 years | -22% | -13.7M shares |
| 5 years | -24% | -15.4M shares |
| Available history | -33% | -23.8M shares |
CROX has the edge over RIVN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $250M |
| Q2 2026 | $256.2M |
| Q1 2026 | — |
| Q4 2025 | $180.2M |
| Q3 2025 | $208M |
| Q2 2025 | $133.3M |
| Q1 2025 | $60.9M |
| Q4 2024 | $226.3M |
CROX spent $686M buying back its own shares over the past year, up 9.2% from the year before.
RIVN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.1% | +121M shares |
| 1 year | +19% | +226M shares |
| 3 years | +52% | +494M shares |
RIVN has 1.4B diluted shares, up 19% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | $6M |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CROX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.1x | Healthy |
| Q2 2026 | 1.2x | Healthy |
| Q1 2026 | 5.8x | High |
| Q4 2025 | 4.8x | High |
| Q3 2025 | 4.2x | High |
| Q2 2025 | 3.5x | Elevated |
| Q1 2025 | 1.2x | Healthy |
| Q4 2024 | 1.1x | Healthy |
CROX's net debt is about 1.1 years of its operating earnings (EBITDA), down from 4.2 years a year ago.
RIVN Net Leverage
RIVN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CROX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.6 | Neutral |
| Stochastic | 88.0 | Overbought |
CROX's weekly RSI is 69 (neutral) and its Stochastic is 88 (overbought).
RIVN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.5 | Neutral |
| Stochastic | 25.6 | Neutral |
RIVN's weekly RSI is 41 (neutral) and its Stochastic is 26 (neutral).
CROX PE vs Consumer Cyclical Sector
| Metric | CROX | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 18x | 34% below |
| PE % | 57 | 47 | 10 pts above |
CROX is trading at 12x earnings, a 34% discount to the Consumer Cyclical sector's median of 18x.
RIVN PE vs Consumer Cyclical Sector
RIVN has no meaningful PE right now: it lost money over the past year.
CROX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $132.6 | 18% above |
| 20 week MA | $129.2 | 21% above |
| 50 week MA | $109.7 | 43% above |
| 100 week MA | $102.8 | 53% above |
| 200 week MA | $110.2 | 42% above |
CROX has the edge over RIVN on trend strength, trading above more of its moving averages.
RIVN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.3 | 3.9% below |
| 20 week MA | $15.1 | 15% below |
| 50 week MA | $15.9 | 19% below |
| 100 week MA | $14.7 | 13% below |
| 200 week MA | $15.1 | 15% below |
RIVN is in a downtrend: it's below all five of its weekly moving averages, and 15% below its 200-week average.
CROX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $41.3 | $62.7 | +52% |
| 2021 | $62.7 | $123.5 | +97% |
| 2022 | $123.5 | $103.0 | -17% |
| 2023 | $103.0 | $93.4 | -9.3% |
| 2024 | $93.4 | $110.7 | +19% |
| 2025 | $110.7 | $91.6 | -17% |
| 2026 YTD | $91.6 | $156.9 | +71% |
CROX has the edge over RIVN on returns for 2026, with the stronger performance.
RIVN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $130.0 | $96.8 | -25% |
| 2022 | $96.8 | $19.1 | -80% |
| 2023 | $19.1 | $23.5 | +23% |
| 2024 | $23.5 | $13.7 | -42% |
| 2025 | $13.7 | $20.9 | +53% |
| 2026 YTD | $20.9 | $12.8 | -39% |
RIVN has finished lower in three of the last five years. It's down 39% so far in 2026.